3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Breast
18
Gastrointestinal
12
Gynecologic
6
Tumor-Agnostic
4
Thoracic
3
Sarcoma
3
CNS
3
Head & Neck
2
Genitourinary
2
Dermatologic
1
Conditions
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Astrocytoma
1
Anus Neoplasms
1
Adenocarcinoma
1
Interventions
Magnetic Resonance Spectroscopy
63
Specimen Handling
58
pembrolizumab
40
enzalutamide
38
Nivolumab
32
Gemcitabine
30
Docetaxel
28
Biopsy
25
Prednisone
23
Abiraterone Acetate
21
apalutamide
20
Androgen Antagonists
19
Radiosurgery
18
Cisplatin
18
darolutamide
16
cabozantinib
16
abiraterone
16
Radiotherapy
16
enfortumab vedotin
15
Radiation
14
Ipilimumab
13
belzutifan
12
Pluvicto
12
Mitomycin
12
olaparib
11
erdafitinib
11
durvalumab
11
atezolizumab
11
X-Rays
10
Standard of Care
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
trastuzumab deruxtecan
×
Genitourinary
×
30 days
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled